glp-1-vs-gip-research.
Introduction
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones secreted by the gut in response to nutrient intake. Both amplify insulin secretion, but their mechanisms and tissue distributions differ.
GLP-1 Receptor Signalling
- Released by L-cells in the ileum and colon
- Stimulates glucose-dependent insulin secretion
- Suppresses glucagon release
- Slows gastric emptying
- Reduces appetite via hypothalamic pathways
GIP Receptor Signalling
- Released by K-cells in the duodenum
- Potent insulin secretagogue under hyperglycaemic conditions
- Plays a role in lipid storage and adipocyte function
- May complement GLP-1 in body weight and glycaemic control
Dual and Triple Agonists
| Approach | Targets | Research Focus |
|---|---|---|
| GLP-1RA | GLP-1R | Glycaemic control, weight loss, cardiovascular |
| GIP/GLP-1 co-agonist | GIPR + GLP-1R | Enhanced weight loss, improved lipid profile |
| Triple agonist | GIPR + GLP-1R + GCGR | Energy expenditure, hepatic fat, glycaemia |
Clinical Translation
Tirzepatide, a GIP/GLP-1 co-agonist, has demonstrated superior glycaemic and weight outcomes compared to selective GLP-1 agonists in clinical trials, validating the incretin co-agonism hypothesis.
Conclusion
Understanding GLP-1 and GIP biology is essential for modern metabolic peptide research. Dual and triple agonist strategies represent the next frontier in incretin-based therapeutics.
Related Products
- Buy Gut Inflammation Research (BPC/KPV/Larazotide)
Explore Simplex Peptides
- Browse research peptides for sale